Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 13 Mar 2025
Seikagaku announces receipt of a complete response letter concerning the biologics license application in the US for SI-6603 (condoliase)
12 March 2025 - Seikagaku announced today that it has received from the US FDA a complete response letter concerning ...
Posted by Michael Wonder on 13 Mar 2025
First daily pill for endometriosis approved for NHS use
13 March 2025 - Today we've recommended the first long-term daily pill to treat endometriosis that could transform how this painful ...
Posted by Michael Wonder on 12 Mar 2025
Atsena Therapeutics granted US FDA fast track designation for ATSN-201 gene therapy to treat X-linked retinoschisis
12 March 2025 - Marks third FDA designation for ATSN-201, which has also received rare paediatric disease designation and orphan drug ...
Posted by Michael Wonder on 12 Mar 2025
Sydnexis announces FDA acceptance of new drug application and PDUFA date for SYD-101 for the treatment of progression of paediatric myopia
11 March 2025 - Sydnexis today announced that the US FDA has accepted its new drug application for SYD-101 and ...
Posted by Michael Wonder on 12 Mar 2025
PHARMAC to fund more cancer medicines (March 2025)
12 March 2025 - PHARMAC is funding six more medicines for cancers and one for antibiotic resistant infections. ...
Posted by Michael Wonder on 12 Mar 2025
Geron announces European Commission approval of Rytelo (imetelstat), a first in class telomerase inhibitor, for the treatment of adults with transfusion-dependent anaemia due to lower risk MDS
11 March 2025 - Rytelo is the first and only telomerase inhibitor approved in the US and Europe. ...
Posted by Michael Wonder on 12 Mar 2025
Celltrion's infliximab, the first monoclonal antibody biosimilar, is now Remdantry in Canada
11 March 2025 - CT-P13, intravenous infliximab, developed and manufactured by Celltrion, is the first monoclonal antibody biosimilar therapy and has ...
Posted by Michael Wonder on 12 Mar 2025
ACCRUFeR (ferric maltol) is now available in Canada as a prescription oral treatment for iron deficiency anaemia
11 March 2025 - ACCRUFeR is the only oral iron therapy approved as a prescription drug in Canada. ...
Posted by Michael Wonder on 12 Mar 2025
Atezolizumab for the first-line treatment of adults with advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable
12 March 2025 - NICE is unable to make a recommendation on the use of atezolizumab (Tecentriq) in the NHS for ...
Posted by Michael Wonder on 12 Mar 2025
Zolbetuximab in combination with chemotherapy for the first-line treatment of adults with claudin-18.2 positive, HER2 negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinoma (final guidance)
12 March 2025 - NICE has published final evidence-based recommendations on the use of zolbetuximab (Vyloy) in combination with chemotherapy ...
Posted by Michael Wonder on 12 Mar 2025
Natalizumab for the treatment of patients with highly active relapsing–remitting multiple sclerosis after disease-modifying therapy
12 March 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 11 Mar 2025
PHARMAC funds new oral contraceptive pill
11 March 2025 - PHARMAC has decided to fund a new progestogen only oral contraceptive pill called desogestrel (Cerazette). ...
Posted by Michael Wonder on 11 Mar 2025
ICER to assess treatment for non-cystic fibrosis bronchiectasis
11 March 2025 - Report will be subject of CTAF meeting in September 2025; draft scoping document open to public ...
Posted by Michael Wonder on 11 Mar 2025
Health Canada authorises Lazcluze (lazertinib) in combination with Rybrevant (amivantamab) as a first-line chemotherapy-free treatment for patients with EGFR-mutated advanced lung cancer
10 March 2025 - Phase 3 MARIPOSA study showed Lazcluze plus Rybrevant significantly improved progression-free survival, reducing the risk of ...
Posted by Michael Wonder on 10 Mar 2025
SMC - March 2025 decisions
10 March 2025 - The SMC, which advises on newly licensed medicines for use by NHSScotland, has today published advice ...